

**REMARKS/ARGUMENTS**

Upon entering the above amendments to the claims, claims 58, 59, 70 and 105-117 will be pending in this application. Claim 1-57, 60-69 and 71-104 are canceled, Claims 58, 59, 70 and 105 are amended and Claims 106-117 are new. Claims 58, 59, 70 and 105 are amended to correct formalities, remove non-elected subject matter and/or correct claim dependencies. Support for new claim 106 can be found in the last sentence of paragraph [0072] of the specification. New claims 107-109 find support in paragraph [0067] of the specification. Support for new claims 110-111 can be found in paragraph [0068] of the specification. New claim 112 finds support in paragraph [0071] of the specification. Support for new claim 113 can be found in original claims 62 and 67 and support for new claim 114 can be found in original claim 69. The new claims 115-118 are presented to particular compounds 950, 687 and 425, recited in Tables 7, 14 and 13, respectively. Applicants believe no new matter is present in any portion of the preliminary amendment and respectfully request that the amendment be entered for substantive examination. Applicants amendment is made without prejudice or disclaimer and Applicants reserve the right to pursue any amended or canceled subject matter in a subsequent divisional or continuation application.

In this second restriction requirement, the Examiner has requested election of one of 22 inventions. In response to the restriction requirement, Applicants provisionally elect to prosecute the invention of Group I (claims 1, drawn to compounds of formula (I)). Applicants request that upon allowance of the claims, the Examiner consider rejoinder of withdrawn species if they are embraced by the allowed generic claims pursuant to MPEP § 809.03(c)(B).

In response to the Examiner's request for an election of species, Applicants further elect the compound 1-adamantan-1-yl-3-(12-dodecanoic acid)-urea. The compound is described as compound 687 in Table 14. Claims readable thereon include claims wherein R<sup>1</sup> is C<sub>5</sub>-C<sub>12</sub> cycloalkyl; P<sup>1</sup> is -NHC(O)NH-, P<sup>2</sup> is (CO<sub>2</sub>R<sup>2</sup>); R<sup>2</sup> is H, n is 0, m is 1; and L<sup>1</sup> and L<sup>2</sup> is an substituted or unsubstituted C<sub>2</sub>-C<sub>12</sub> alkylene.

**CONCLUSION**

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for substantive review on their merits.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5014.

Respectfully submitted,



Mark H. Hopkins, Ph.D.  
Reg. No. 44,775

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 415-576-0300  
Attachments  
M3H:dmd  
60844775 v1